Atherogenic Lipoprotein Particles in Atherosclerosis

The importance of low-density lipoprotein (LDL) cholesterol in the development of atherosclerosis has long been recognized, and LDL cholesterol remains the primary target of therapy for the prevention of coronary heart disease. Nevertheless, increasing research attention over the past decade has been devoted to the heterogeneity of LDL particles and the atherogenicity of lipids and lipoproteins other than LDL. Particularly atherogenic forms of LDL include small, dense LDL particles and oxidized LDL. All lipoproteins that contain apolipoprotein B, such as LDL, very-low-density lipoprotein, and intermediate-density lipoprotein, tend to promote atherosclerosis; however, these particles differ in their apolipoprotein and triglyceride content. High levels of plasma triglycerides increase the risk of acute coronary events. Lipoprotein(a) is now considered an independent risk factor in both men and women. Ultimately, better understanding of the roles of these lipid particles and subfractions in the initiation and progression of atherosclerosis may affect treatment decisions.

[1]  A. Hamsten,et al.  LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[3]  T. Lehtimäki,et al.  The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. , 1998, Free radical research.

[4]  M. Taskinen,et al.  Association Between Carotid Intima-Media Thickness and Low-Density Lipoprotein Size and Susceptibility of Low-Density Lipoprotein to Oxidation in Asymptomatic Members of Familial Combined Hyperlipidemia Families , 2002, Stroke.

[5]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[6]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[7]  A. del Río.  [Lipoprotein (a)]. , 1991, Medicina clinica.

[8]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[9]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Freedman,et al.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[11]  I. Lemieux,et al.  The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. , 1999, Diabetes & metabolism.

[12]  F. Van de Werf,et al.  Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[13]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[14]  R. Krauss,et al.  Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. , 1992, Journal of lipid research.

[15]  I. Tkáč,et al.  The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  I. Holme,et al.  Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. , 1998, Clinical chemistry.

[17]  P. Wilson,et al.  Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. , 1999, Clinical chemistry.

[18]  M. Taskinen,et al.  Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS) , 2003, Circulation.

[19]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. , 1993 .

[20]  G. Thorgeirsson,et al.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. , 1992, The American journal of cardiology.

[21]  H Yasue,et al.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[22]  D. Arveiler,et al.  Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. , 1996, Journal of lipid research.

[23]  R. Krauss,et al.  Atherogenicity of triglyceride-rich lipoproteins. , 1998, The American journal of cardiology.

[24]  J. Segrest,et al.  Quantification of cholesterol in all lipoprotein classes by the VAP-II method. , 1994, Journal of lipid research.

[25]  D. Swinkels,et al.  Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. , 1987, Journal of lipid research.

[26]  G. Dagenais,et al.  A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. , 2001, The Canadian journal of cardiology.

[27]  R. Heine,et al.  Measurement of LDL particle size in whole plasma and serum by high performance gel-filtration chromatography using a fluorescent lipid probe. , 1998, Clinical chemistry.

[28]  J P Segrest,et al.  High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method. , 1981, Journal of lipid research.

[29]  G. Dagenais,et al.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.

[30]  J. Coresh,et al.  Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. , 1992, The American journal of cardiology.

[31]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[32]  Alice Arnold,et al.  Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[33]  M. Uusitupa,et al.  Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[34]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[35]  B. Fagerberg,et al.  Circulating Oxidized LDL Is Associated With Subclinical Atherosclerosis Development and Inflammatory Cytokines (AIR Study) , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[36]  A. Tenenbaum,et al.  Coronary Artery Disease but Not Coronary Calcification Is Associated with Elevated Levels of Cardiolipin, Beta-2-Glycoprotein-I, and Oxidized LDL Antibodies , 2001, The Cardiology.

[37]  T. Orchard,et al.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.

[38]  P. Ridker,et al.  Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.

[39]  D. Steinberg,et al.  Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? , 2002, Circulation.

[40]  R. Havel.  Role of triglyceride-rich lipoproteins in progression of atherosclerosis. , 1990, Circulation.

[41]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[42]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[43]  D. M. Lee,et al.  Composition and concentration of apolipoproteins in very-low-and low-density lipoproteins of normal human plasma. , 1974, Atherosclerosis.

[44]  M. Kurabayashi,et al.  Circulating Oxidized Low Density Lipoprotein Levels: A Biochemical Risk Marker for Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[45]  P. Wilson,et al.  Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. , 2002, Diabetes care.

[46]  D. Waters,et al.  Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events , 1993, Circulation.

[47]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[48]  W. Mack,et al.  The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[49]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[50]  P. Cullen.  Evidence that triglycerides are an independent coronary heart disease risk factor. , 2000, The American journal of cardiology.